Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
547 Reprogramming of type I interferon-responding tumor-reactive T lymphocytes associates with improved outcomes to neoadjuvant doublet immunotherapy in HNSCC
Compose a Response to This Article
Other responses
No responses have been published for this article.
